Therapeutic potential of induced pluripotent stem cells for spinal cord injury

Satoshi Nori, Osahiko Tsuji, Yohei Okada, Yoshiaki Toyama, Hideyuki Okano, Masaya Nakamura

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Once the safety issue has been overcome, induced pluripotent stem cells (iPSCs), which do not entail ethical or immunological concerns, may become the preferred cell source for regenerative medicine. Various types of iPSCs have been established by different methods, and each type exhibits different biological properties. Before iPSC-based clinical applications can be initiated, detailed evaluations of the cells, including their differentiation potentials and tumorigenic activities in different contexts, should be investigated to establish their safety and effectiveness for cell transplantation therapies. Recently, we demonstrated the directed neural differentiation of mouse iPSCs and examined their therapeutic potential in a mouse spinal cord injury (SCI) model. Mouse iPSC-derived neural stem/progenitor cells (NS/PCs), which had been pre-evaluated as non-tumorigenic by their transplantation into nonobese diabetic-severe combined immunodeficiency (NOD-scid) mouse brain, were transplanted into the spinal cord 9 days after SCI. Mouse iPSC-derived NS/PCs differentiated into all three neural lineages without forming teratomas or other tumors. They also participated in re-myelination and induced the axonal re-growth, promoting motor functional recovery. Nevertheless, our results constitute only the first step toward clinical application. The safety and effectiveness of human iPSC-derived NS/PCs need to be more intensively investigated in future preclinical studies, for example, using non-human primate SCI models. In particular, human iPSCs established by delivering reprogramming factors using a safer method than retrovirus system, such as an integration-free virus system, virus-free system, or transgene-free system should be evaluated.

Original languageEnglish
Pages (from-to)17-27
Number of pages11
JournalBrain and Nerve
Volume64
Issue number1
Publication statusPublished - 2012 Jan 1

Fingerprint

Induced Pluripotent Stem Cells
Spinal Cord Injuries
Neural Stem Cells
Stem Cells
Therapeutics
Safety
Virus Integration
Severe Combined Immunodeficiency
Regenerative Medicine
Teratoma
Cell Transplantation
Retroviridae
Cell- and Tissue-Based Therapy
Transgenes
Primates
Spinal Cord
Transplantation
Viruses
Brain
Growth

Keywords

  • Cell transplantation therapy
  • Induced pluripotent stem cells (iPSCs)
  • Neural stem/progenitor cells (NS/PCs)
  • Regenerative medicine
  • Spinal cord injury

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Therapeutic potential of induced pluripotent stem cells for spinal cord injury. / Nori, Satoshi; Tsuji, Osahiko; Okada, Yohei; Toyama, Yoshiaki; Okano, Hideyuki; Nakamura, Masaya.

In: Brain and Nerve, Vol. 64, No. 1, 01.01.2012, p. 17-27.

Research output: Contribution to journalArticle

Nori, Satoshi ; Tsuji, Osahiko ; Okada, Yohei ; Toyama, Yoshiaki ; Okano, Hideyuki ; Nakamura, Masaya. / Therapeutic potential of induced pluripotent stem cells for spinal cord injury. In: Brain and Nerve. 2012 ; Vol. 64, No. 1. pp. 17-27.
@article{a41efdcf99514f888f2a1015349a5fa3,
title = "Therapeutic potential of induced pluripotent stem cells for spinal cord injury",
abstract = "Once the safety issue has been overcome, induced pluripotent stem cells (iPSCs), which do not entail ethical or immunological concerns, may become the preferred cell source for regenerative medicine. Various types of iPSCs have been established by different methods, and each type exhibits different biological properties. Before iPSC-based clinical applications can be initiated, detailed evaluations of the cells, including their differentiation potentials and tumorigenic activities in different contexts, should be investigated to establish their safety and effectiveness for cell transplantation therapies. Recently, we demonstrated the directed neural differentiation of mouse iPSCs and examined their therapeutic potential in a mouse spinal cord injury (SCI) model. Mouse iPSC-derived neural stem/progenitor cells (NS/PCs), which had been pre-evaluated as non-tumorigenic by their transplantation into nonobese diabetic-severe combined immunodeficiency (NOD-scid) mouse brain, were transplanted into the spinal cord 9 days after SCI. Mouse iPSC-derived NS/PCs differentiated into all three neural lineages without forming teratomas or other tumors. They also participated in re-myelination and induced the axonal re-growth, promoting motor functional recovery. Nevertheless, our results constitute only the first step toward clinical application. The safety and effectiveness of human iPSC-derived NS/PCs need to be more intensively investigated in future preclinical studies, for example, using non-human primate SCI models. In particular, human iPSCs established by delivering reprogramming factors using a safer method than retrovirus system, such as an integration-free virus system, virus-free system, or transgene-free system should be evaluated.",
keywords = "Cell transplantation therapy, Induced pluripotent stem cells (iPSCs), Neural stem/progenitor cells (NS/PCs), Regenerative medicine, Spinal cord injury",
author = "Satoshi Nori and Osahiko Tsuji and Yohei Okada and Yoshiaki Toyama and Hideyuki Okano and Masaya Nakamura",
year = "2012",
month = "1",
day = "1",
language = "English",
volume = "64",
pages = "17--27",
journal = "Brain and Nerve",
issn = "0006-8969",
publisher = "Igaku-Shoin Ltd",
number = "1",

}

TY - JOUR

T1 - Therapeutic potential of induced pluripotent stem cells for spinal cord injury

AU - Nori, Satoshi

AU - Tsuji, Osahiko

AU - Okada, Yohei

AU - Toyama, Yoshiaki

AU - Okano, Hideyuki

AU - Nakamura, Masaya

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Once the safety issue has been overcome, induced pluripotent stem cells (iPSCs), which do not entail ethical or immunological concerns, may become the preferred cell source for regenerative medicine. Various types of iPSCs have been established by different methods, and each type exhibits different biological properties. Before iPSC-based clinical applications can be initiated, detailed evaluations of the cells, including their differentiation potentials and tumorigenic activities in different contexts, should be investigated to establish their safety and effectiveness for cell transplantation therapies. Recently, we demonstrated the directed neural differentiation of mouse iPSCs and examined their therapeutic potential in a mouse spinal cord injury (SCI) model. Mouse iPSC-derived neural stem/progenitor cells (NS/PCs), which had been pre-evaluated as non-tumorigenic by their transplantation into nonobese diabetic-severe combined immunodeficiency (NOD-scid) mouse brain, were transplanted into the spinal cord 9 days after SCI. Mouse iPSC-derived NS/PCs differentiated into all three neural lineages without forming teratomas or other tumors. They also participated in re-myelination and induced the axonal re-growth, promoting motor functional recovery. Nevertheless, our results constitute only the first step toward clinical application. The safety and effectiveness of human iPSC-derived NS/PCs need to be more intensively investigated in future preclinical studies, for example, using non-human primate SCI models. In particular, human iPSCs established by delivering reprogramming factors using a safer method than retrovirus system, such as an integration-free virus system, virus-free system, or transgene-free system should be evaluated.

AB - Once the safety issue has been overcome, induced pluripotent stem cells (iPSCs), which do not entail ethical or immunological concerns, may become the preferred cell source for regenerative medicine. Various types of iPSCs have been established by different methods, and each type exhibits different biological properties. Before iPSC-based clinical applications can be initiated, detailed evaluations of the cells, including their differentiation potentials and tumorigenic activities in different contexts, should be investigated to establish their safety and effectiveness for cell transplantation therapies. Recently, we demonstrated the directed neural differentiation of mouse iPSCs and examined their therapeutic potential in a mouse spinal cord injury (SCI) model. Mouse iPSC-derived neural stem/progenitor cells (NS/PCs), which had been pre-evaluated as non-tumorigenic by their transplantation into nonobese diabetic-severe combined immunodeficiency (NOD-scid) mouse brain, were transplanted into the spinal cord 9 days after SCI. Mouse iPSC-derived NS/PCs differentiated into all three neural lineages without forming teratomas or other tumors. They also participated in re-myelination and induced the axonal re-growth, promoting motor functional recovery. Nevertheless, our results constitute only the first step toward clinical application. The safety and effectiveness of human iPSC-derived NS/PCs need to be more intensively investigated in future preclinical studies, for example, using non-human primate SCI models. In particular, human iPSCs established by delivering reprogramming factors using a safer method than retrovirus system, such as an integration-free virus system, virus-free system, or transgene-free system should be evaluated.

KW - Cell transplantation therapy

KW - Induced pluripotent stem cells (iPSCs)

KW - Neural stem/progenitor cells (NS/PCs)

KW - Regenerative medicine

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84859394566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859394566&partnerID=8YFLogxK

M3 - Article

C2 - 22223498

AN - SCOPUS:84859394566

VL - 64

SP - 17

EP - 27

JO - Brain and Nerve

JF - Brain and Nerve

SN - 0006-8969

IS - 1

ER -